Navigation Links
Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results
Date:11/6/2008

evelopment, regulatory filings and actions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors, as well as the Company's subsequent quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables.)

ONYX PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

------------------ ------------------

2008 2007 2008 2007

Net revenue from -------- ------- -------- --------

unconsolidated joint

business $39,924 $17,635 $107,860 $28,131

Operating expenses:

Research and development

(1) 10,950 7,901 27,012 19,883

Selling, general and

administrative (1) 19,319 15,245 58,985 44,140

-------- ------- -------- --------

Total operating expenses 30,269 23,146 85
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
8. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
9. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
10. Genesis Pharmaceuticals Files Counter Claims
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... MD The Endocrine Society,s 91st Annual Meeting, ENDO 09 ... Center in Washington, DC, June 10-13, 2009. Approximately 7,500 ... expected to assemble for this premier meeting of hormone ... an opportunity for journalists to learn about the latest ...
... possible, transplanting stem cells from the patient,s own bone marrow is ... , The procedure has been tested successfully in the ... shown in 80% of cases, and considerable improvement in quality of ... Clnic has used this therapy in a total of 6 patients. ...
... RiskAnalyzer Incorporates Johns Hopkins ACG System for Provider ... Ala., Feb. 19 ... its new Medicare risk adjustment software, DSTHS RiskAnalyzer(TM). ... coding is not capturing disease conditions under the ...
... hospital clients received unexpected checks totaling nearly $4.4 ... from $65,000 to more than $750,000 - were ... unique and innovative partnership between the hospital management ... the QHR/Gallagher Retro Insurance Program, hospital groups that ...
... correlate relationship with the invasion and metastasis of ... N-cadherin may promote motility and invasion in carcinoma ... and N-cadherin expressions in esophageal squamous cell carcinoma ... Fan from China detected the expression of E-cadherin ...
... Roughly 100,000 Swedes are under treatment with the blood-thinning ... which makes the initiation of treatment a risky balancing ... at Uppsala University have developed a model for calculating ... appears in the scientific publication New England Journal ...
Cached Medicine News:Health News:News media registration opens for ENDO 09 in Washington, D.C. 2Health News:New therapy with stem cells to treat Crohn's disease 2Health News:New therapy with stem cells to treat Crohn's disease 3Health News:New therapy with stem cells to treat Crohn's disease 4Health News:New therapy with stem cells to treat Crohn's disease 5Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... 2012  IRIDEX Corporation (NASDAQ: IRIX ) today ... at investment conferences this month. The Company ... Technology Snowbird Conference where President and CEO Dominik Beck ... investors throughout the day.  The Company ...
... March 1, 2012 Alere Inc. (NYSE: ... of their health at home through the merger of rapid diagnostics ... share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B).  ... record of Series B stock at the close of business on ...
Cached Medicine Technology:
... Over the last 25 years, Bio-logic has ... ,The company that introduced the first Digital ... epilepsy monitoring to you! Ceegraph VISION is ... can be expanded to integrate all your ...
... Digital EEG ,The company that introduced ... the latest addition to the Ceegraph ... innovative system incorporates the latest developments ... management to offer you unprecedented portability, ...
... When you purchase an XLTEK Mobee, you're ... in one. Both the Mobee32 and the Mobee ... ambulatory PSG recording, traditional in-lab EEG monitoring, or ... channels that allow for full 10/20 electrode placement. ...
... headboxes are the latest ... of portable battery-powered EEG ... robust new mechanical design, ... XLTEK's standard MOBEE24plus and ...
Medicine Products: